UPC_CFI_120/2025 – Tandem v Roche
- Court
- Court of Appeal
- Date
- Outcome
- Granted
- Sector
- Other
- Decision Type
- PROCEDURAL
Expert Commentary
Settlement Background Tandem’s revocation action was dismissed by the Paris Central Division. Tandem appealed. The parties subsequently informed the Court of Appeal that they had reached a settlement, which they wanted to be confirmed by the Court of Appeal and kept confidential. Parties would bear their own costs. Court of Appeal The Court of Appeal granted the request and ordered the decision and the agreement in redacted version to be entered in the Register. The Court of appeal further stated: “This decision is enforceable as a final decision of the Court of Appeal.” Comment 1. This decision is based on R. 365 RoP. 2. It is important to note that the Court explicitly states that he confidentiality of the agreement can be challenged by a member of the public and that only then the Court of Appeal will decide about the confidentiality. So basically the Court of Appeal refused to make a decision about whether or not a member of the public would obtain access before such a request is made. That is understandable, as you do not know before an Art. 262 RoP is made what exactly the reasons are why such member of the public thinks that the agreement or parts of it should not remain secret. On the other hand this leads to uncertainty for the parties to the agreement. That may be the price you have to pay for the fact that “the decision to confirm one settlement may be enforced as a final decision of the Court” (the meaning of which I discussed in an earlier edition of “UPC Unfiltered”).
Full Decision Text
1 ORDER of the Court of Appeal of the Unified Patent Court issued on 3 June 2025 concerning a confirmation of a settlement APPELLANTS ( AND CLAIMANTS BEFORE THE COURT OF FIRST INSTANCE ) 1. Tandem Diabetes Care Europe B.V., Schiphol Boulevard 359, WTC Schiphol Airport, D-Tower 11th floor, 1118 BJ, Schiphol, The Netherlands 2. Tandem Diabetes Care, Inc., 12400 High Bluff Drive, CA 92130, San Diego, USA (hereinafter jointly referred to as ‘Tandem Diabetes ‘) both represented by attorney-at-law Christian Dekoninck, Taylor Wessing, Brussels, Belgium, and other representatives from that firm as well as from AOMB, Eindhoven, The Netherlands R ESPONDENT ( AND D EFENDANT BEFORE THE COURT OF FIRST INSTANCE ) Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305, Mannheim, Germany (hereinafter ‘Roche Diabetes ‘) represented by attorney-at-law Dr. Christof Augenstein, Kather Augenstein, Düsseldorf, Germany, and other representatives from that firm as well as from Grünecker Patent- und Rechtsanwälte, Munich, Germany P ATENT AT ISSUE EP 2 196 231 P ANEL AND D ECIDING JUDGES Panel 2 Rian Kalden, presiding judge and legally qualified judge Ingeborg Simonsson, legally qualified judge and judge-rapporteur Patricia Rombach, legally qualified judge Jeroen Meewisse, technically qualified judge Stefan Wilhelm, technically qualified judge UPC Court of Appeal UPC_CoA_120/2025 APL_7604/2025 App_24387/2025 App_24411/2025 App_24847/2025 2 IMPUGNED D ECISION OF THE COURT OF FIRST INSTANCE Central Division Paris, 18 December 2024, revocation action ACT_589997/2023, UPC_CFI_454/2023 L ANGUAGE OF THE CASE English SUMMARY OF FACTS 1. Tandem Diabetes lodged an action for revocation of the patent at issue, relating to a system for ambulatory drug infusion, against Roche Diabetes before the Central Division Paris. 2. In the impugned decision, the Central Division dismissed the revocation action, maintained the patent at issue as granted and ordered that the costs of the proceedings should be borne by Tandem Diabetes. 3. Tandem Diabetes appealed. The parties then informed the Court that they had concluded the proceedings by way of settlement. REQUESTS OF THE PARTIES 4. Both parties request that the Court of Appeal I. confirm that the parties have concluded the Settlement Agreement according to Annex BBY 1; II. order that details of the settlement are confidential; III. confirm that each party bears its own costs and that no costs shall be reimbursed between the parties. R EASONS 5. According to R. 365 RoP, if requested by the parties, the Court shall confirm the settlement that they have reached. Such decision may be enforced as a final decision of the Court and shall be entered on the Register. 6. The R. 262.2 RoP request will be decided once a R. 262.1(b) RoP request is made by a member of the public. 7. The Settlement Agreement contains confidential information. O RDER I. At the request of the parties the Court of Appeal confirms, pursuant to R. 365.1 RoP, that the parties have concluded the following Settlement Agreement : 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 II. This settlement terminates the proceedings before the Court of Appeal pending under UPC_CoA_120/2025, APL_7604/2025. III. The Court of Appeal confirms that each party shall bear its own costs and that no costs shall be reimbursed between the parties. IV. This decision in the redacted version shall be entered on the register; V. This decision is enforceable as a final decision of the Court of Appeal. Issued on 3 June 2025 Rian Kalden, presiding judge and legally qualified judge Ingeborg Simonsson, legally qualified judge and judge-rapporteur Patricia Rombach, legally qualified judge Jeroen Meewisse, technically qualified judge Stefan Wilhelm, technically qualified judge For the Registry
Key Holdings
- Settlement confirmed on appeal (R. 365 RoP).
- Redacted agreement entered in Register.
- Decision on confidentiality deferred until public access request.
Tags
- Confidentiality
- Enforcement
- Public Access
- Settlement